Tnf Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Q/C Technologies, formerly TNF Pharmaceuticals, has pivoted its business strategy to energy-efficient blockchain and high-performance computing, securing new capital and acquiring an exclusive license for laser processing units.
TNF Pharmaceuticals, Inc. reported a significant reduction in net loss for the first half of 2025, driven by non-cash gains, but faces ongoing liquidity challenges and Nasdaq listing compliance issues.
TNF Pharmaceuticals reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also facing potential delisting from Nasdaq.
10-Q: TNF Pharmaceuticals Reports Q3 2024 Results, Cites Ongoing Development of MYMD-1 and Supera-CBD
TNF Pharmaceuticals reported its Q3 2024 financial results, highlighting ongoing development of its MYMD-1 and Supera-CBD therapeutic platforms and recent financing activities.
TNF Pharmaceuticals amended warrants related to recent preferred stock offerings and reported a net loss of $19.3 million for the first half of 2024.
MyMD Pharmaceuticals reported a net loss of $11 million for Q1 2024 and is facing substantial doubt about its ability to continue as a going concern.